Jørgensen P E, Raaberg L, Poulsen S S, Nexø E
Institute of Medical Anatomy, Department B, University of Copenhagen, Denmark.
Regul Pept. 1990 Nov 15;31(2):115-24. doi: 10.1016/0167-0115(90)90114-c.
The present study on the rat shows that i.v. administration of the proteinase inhibitor aprotinin reduces the urinary output of immunoreactive epidermal growth factor (EGF) while the amount of immunoreactive EGF in the kidneys is increased. This indicates that the EGF-precursor in the rat kidney in vivo is processed by an aprotinin inhibitable proteinase. EGF is produced in the kidneys as a precursor with a molecular weight of approximately 130 kDa. In rat urine, nanomolar amounts of 6 kDa EGF are excreted per 24 h together with small amounts of high molecular weight forms of EGF. During i.v. administration of aprotinin the median urinary output of immunoreactive EGF is reduced to 15% of the excretion of control rats (23 pmol/2 h versus 157 pmol/2 h, P less than 0.001). Especially the excretion of 6 kDa EGF is reduced (median excretion 12 pmol/2 h versus 134 pmol/2 h, P less than 0.001). The amount of immunoreactive EGF in the kidney tissue is increased after aprotinin administration (median amount 0.11 pmol EGF/mg protein versus less than 0.04 pmol EGF/mg protein, P less than 0.001). Neither the creatinine clearance, the total urinary protein output, nor the volume of urine produced was affected by aprotinin.
对大鼠的当前研究表明，静脉注射蛋白酶抑制剂抑肽酶可降低免疫反应性表皮生长因子（EGF）的尿量输出，而肾脏中免疫反应性EGF的量会增加。这表明大鼠肾脏中的EGF前体在体内是由一种可被抑肽酶抑制的蛋白酶加工的。EGF在肾脏中以前体形式产生，其分子量约为130 kDa。在大鼠尿液中，每24小时会排出纳摩尔量的6 kDa EGF以及少量高分子量形式的EGF。在静脉注射抑肽酶期间，免疫反应性EGF的中位尿量输出降至对照大鼠排泄量的15%（23 pmol/2小时对157 pmol/2小时，P<0.001）。尤其是6 kDa EGF的排泄减少（中位排泄量12 pmol/2小时对134 pmol/2小时，P<0.001）。注射抑肽酶后，肾脏组织中免疫反应性EGF的量增加（中位量0.11 pmol EGF/mg蛋白质对小于0.04 pmol EGF/mg蛋白质，P<0.001）。抑肽酶对肌酐清除率、总尿蛋白输出量或尿量均无影响。
